Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Flerie Invest
Deal Size: $23.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 18, 2021
The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.